Advances in the Diagnosis, Stratification, and Targeted Treatment of Myeloproliferative Neoplasms

Dear Colleagues,

Myeloproliferative neoplasms (MPNs) are a heterogeneous group of hematologic malignancies characterized by the clonal proliferation of one or more myeloid lineages. MPNs include chronic myelogenous leukemia (CML), polycythemia vera, primary myelofibrosis, essential thrombocythemia, chronic neutrophilic leukemia, and chronic eosinophilic leukemia. Recent advances in molecular genetics, genomics, and diagnostic technologies have significantly improved our understanding of MPN pathogenesis, enabling more precise disease classification, risk stratification, and personalized therapeutic strategies.

This Special Issue aims to highlight research on the diagnosis, molecular characterization, and targeted treatment of MPNs, including novel biomarkers, mutational profiling, and innovative therapeutic approaches. We particularly welcome contributions addressing the integration of molecular diagnostics into clinical practice, mechanisms of disease progression, therapy resistance, and the development of next-generation targeted treatments. By bringing together basic and clinical research, this Special Issue provides a comprehensive overview of current and future directions in MPN management, encourages translational research, and supports the development of new strategies to improve patient care.

Dr. Bojana Beleslin Čokić
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.